Top Updates Back
Noir Immune BioTech Inc.
ノイルイミューン・バイオテック株式会社
Noile-Immune Biotech Inc. Alias
2015-04-16
4893
TYO
Japan
Development of novel cancer immunotherapies primarily focused on CAR-T cell therapy
5F, T&G Hamamatsucho Building, 12-10, 2-chome, Shiba, Minato-ku, Tokyo
Koji Tamada
4,047 JPY
25 people
23 people
Company name
Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
タカラバイオ株式会社
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
山口大学
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group Alliance
株式会社日立製作所
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
中外製薬株式会社
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Adaptimmune Limited
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Autolus Limited
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
Millennium Pharmaceuticals, Inc.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
NIB_partner
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
インターフェックス
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
武田薬品工業株式会社
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group
九州大学
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Alliance
東京大学
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Alliance

23 entries
DateDescription
2015-04 Established as a venture company originating from the National Cancer Center (hereinafter referred to as the National Cancer Center) and Yamaguchi University (hereinafter referred to as Yamaguchi University) in Chuo-ku, Tokyo.
2015-04 Established as a venture company originating from the National Cancer Center and Yamaguchi University in Chuo-ku, Tokyo.
2015-04-16 Date of establishment: April 16, 2015.
2015-04-16 Establishment
2015-09 Entered into a joint research agreement with Yamaguchi University.
2015-10 Obtained exclusive implementation license with sublicense rights to third parties for next-generation CAR-T cell platform technology from Yamaguchi University.
2017-08 Partnered with Takeda Pharmaceutical Company (hereinafter referred to as Takeda Pharmaceutical) for joint research and development.
2017-08 Partnered with Takeda Pharmaceutical Company for joint research and development.
2018-12 Signed a license agreement with Takeda Pharmaceutical regarding the derivation of NIB102 and NIB103. (※2)
2018-12 Signed a license agreement with Takeda Pharmaceutical regarding the derivation of NIB102 and NIB103.
2019-03 Relocated headquarters to Minato-ku, Tokyo.
2019-08 Signed a joint development agreement with Adaptimmune Therapeutics plc. (※3)
2019-08 Signed a joint development agreement with Adaptimmune Therapeutics plc.
2019-11 Signed a license agreement with Autolus Therapeutics plc. (※4)
2019-11 Signed a licensing agreement with Autolus Therapeutics plc.
2020-07 Takeda Pharmaceutical commenced Phase I clinical trials of NIB102.
2021-12 Takeda Pharmaceutical commenced Phase I clinical trials of NIB103.
2022-01 Commenced Phase I clinical trials of in-house pipeline NIB101.
2022-08 Signed a license agreement with Chugai Pharmaceutical Co., Ltd.
2023-06 Listed on the Tokyo Stock Exchange Growth Market.
2024-09 Entered into a business partnership agreement for joint development with Takara Bio Inc. (※5, ※6).
2024-09 Signed a business partnership agreement for joint development with Takara Bio Inc.
2025-06 Completed submission of the clinical trial plan for Phase I trials of NIB103.
+ Loaded when opened
1010001167340
Trade nameノイルイミューン・バイオテック株式会社
Trade name (kana)ノイルイミューンバイオテック
Name in English
Corporation type301
Address〒105-0012 東京都港区芝大門２丁目１２番１０号
Postal code1050012
Prefecture code13
City code103
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date2015-10-05
Update date2019-04-19
Change date2019-04-15
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record1
Excluded from search0
Processing type12
Correction type0
Trade name image ID
Address image ID
Sequence number1278930
Source: National Tax Agency Corporate Number Publication Site, basic three items
1010001167340
Corporate number1010001167340
Trade nameノイルイミューン・バイオテック株式会社
Trade name (kana)ノイルイミューンバイオテック
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address東京都港区芝大門２丁目１２番１０号
Postal code1050012
Prefecture東京都
Prefecture code13
City or district港区
City code103
Street address芝大門２丁目１２番１０号
Organisation type301
Processing type12
Correction type0
Status
Representative代表取締役社長　玉田　耕治
Capital4047254000
Employees23
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date2019-04-19
Key information1010001167340
Source: gBizINFO (Ministry of Economy, Trade and Industry)
✅
2026-09-23 02:52 (Model: gpt-4.1-nano )
↑